Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Overactive Bladder Category Switch Prospects Questioned By Indevus

This article was originally published in The Tan Sheet

Executive Summary

Self-selection problems will likely complicate potential Rx-to-OTC switches in the overactive bladder (OAB) category, Indevus Pharmaceuticals execs maintained during an Aug. 9 third quarter earnings call

You may also be interested in...



Merck Seeks Oxytrol Switch For Women As First Overactive Bladder OTC

Merck will present to FDA’s Nonprescription Drugs Advisory Committee Nov. 9 in support of switching Watson’s Oxytrol as a female-specific OTC.

Merck Seeks Oxytrol Switch For Women As First Overactive Bladder OTC

Merck will present to FDA’s Nonprescription Drugs Advisory Committee Nov. 9 in support of switching Watson’s Oxytrol as a female-specific OTC.

Merck Seeks Oxytrol Switch For Women As First Overactive Bladder OTC

Merck will present to FDA’s Nonprescription Drugs Advisory Committee Nov. 9 in support of switching Watson’s Oxytrol as a female-specific OTC.

Related Content

Topics

UsernamePublicRestriction

Register

OM017315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel